论文部分内容阅读
目的:研究宫颈癌肿瘤细胞多药耐药基因1(mdr1)甲基化与宫颈癌新辅助化疗疗效相关性,探索适用于预测临床化疗多药耐药性的敏感指标。方法:采用MassARRY EpiTYPER DNA甲基化分析技术定量分析宫颈鳞癌(n=40)新辅助化疗前后、正常对照组(n=30)中的mdr1基因启动子区15个CpG位点的甲基化状态。结果:新辅助化疗敏感组(n=31)CpG_2、3、4位点甲基化率高于行新辅助化疗耐药组(n=9),差异有统计学意义(p<0.05);与新辅助化疗前组相比,化疗后组CpG_7、CpG_8、CpG_12、13、CpG_18、CpG_19、20、CpG_23、CpG_24位点甲基化率减低,差异有统计学意义(p<0.05);与正常组织(n=30)相比,宫颈癌(n=80)CpG_2、3、4、CpG_5、CpG_6、CpG_7、CpG_8、CpG_9、10、CpG_12、13、CpG_18、CpG_19、20、CpG_22、CpG_23、CpG_24位点甲基化率较低,差异有统计学意义(p<0.05)。结论:宫颈癌mdr1基因甲基化水平高低与宫颈癌NACT疗效有一定相关性。
Objective: To investigate the relationship between methylation of multidrug resistance gene 1 (mdr1) in cervical cancer cells and neoadjuvant chemotherapy in cervical cancer and to explore sensitive indexes suitable for predicting multidrug resistance in clinical chemotherapy. Methods: The methylation of 15 CpG sites in the promoter region of mdr1 gene in the normal control group (n = 30) before and after neoadjuvant chemotherapy of cervical squamous cell carcinoma (n = 40) was quantitatively analyzed by MassARRY EpiTYPER DNA methylation analysis technique status. Results: The methylation rates of CpG2, 3 and 4 in neoadjuvant chemotherapy-sensitive group (n = 31) were significantly higher than those in neoadjuvant chemotherapy-resistant group (n = 9) Compared with the neoadjuvant chemotherapy group, the methylation rates of CpG_7, CpG_8, CpG_12, 13, CpG_18, CpG_19, 20, CpG_23 and CpG_24 sites decreased after chemotherapy, with statistical significance (p <0.05) Cervical cancer (n = 80) CpG_2,3,4, CpG_5, CpG_6, CpG_7, CpG_8, CpG_9,10, CpG_12,13, CpG_18, CpG_19,20, CpG_22, CpG_23, CpG_24 sites The methylation rate was lower, the difference was statistically significant (p <0.05). Conclusion: The methylation level of mdr1 gene in cervical cancer is related to the efficacy of NACT in cervical cancer.